Patent application number | Description | Published |
20100028266 | Composition and methods for treating allergic response - The invention generally relates to compositions and methods for treating and/or preventing an allergic response with reduced rebound hyperemia, comprising highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume, and histamine antagonists. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5. | 02-04-2010 |
20100028267 | Compositions and methods for reducing capillary permeability - The invention generally relates to compositions and methods for reducing capillary permeability. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5. | 02-04-2010 |
20100029659 | Preferential vasoconstriction compositions and methods of use - The invention generally relates to compositions and methods for preferential vasoconstriction of smaller blood vessels relative to larger blood vessels. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5. | 02-04-2010 |
20100029660 | Compositions and methods for reversing rebound hyperemia - The invention generally relates to compositions and methods for inducing vasoconstriction with low incidence of rebound hyperemia. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5. | 02-04-2010 |
20100029661 | Anesthetic compositions and methods of use - The invention generally relates to anesthetic compositions comprising low doses of a selective a-2 adrenergic receptor agonists in combination with anesthetic agents. The invention also relates to methods of using these compositions; in particular, the use of these compositions in humans to enhance the efficacy of a local peripheral anesthetic injection. The compositions and the methods are particularly useful in regional block anesthetic injections, and more particularly, in dental anesthetic injections. | 02-04-2010 |
20100029662 | Vasoconstriction compositions and methods of use - The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5. | 02-04-2010 |
20100029663 | Compositions and methods for reducing activation of alpha-1 receptors - The invention generally relates to compositions and methods for reducing activation of a-1 adrenergic receptors. The compositions comprise highly selective a-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5. | 02-04-2010 |
20100197694 | Compositions and methods for treatment of diseases and conditions with increased vascular permeability - The invention provides compositions and methods for treating diseases and conditions through reducing vascular permeability, selectively inhibiting VEGF-induced postcapillary venular leakage, and/or selectively reducing spread of viral and/or bacterial pathogens. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists having a binding affinity of 300 fold or greater for α-2 over α-1 adrenergic receptors. The compositions preferably comprise brimonidine and/or dexmedetomidine. | 08-05-2010 |
20100202979 | Compositions and methods for treatment of pulmonary diseases and conditions - The invention provides compositions and methods for treating pulmonary diseases and conditions. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists having a binding affinity of 300 fold or greater for α-2 over α-1 adrenergic receptors. The compositions preferably comprise brimonidine and/or dexmedetomidine. | 08-12-2010 |
20100203165 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISORDERS OR CONDITIONS OF THE EYE - The invention provides compositions comprising low concentrations of selective α-2 adrenergic receptor agonists in combination with potassium and/or calcium. Methods for treating eye disorders and conditions are also provided. The compositions preferably comprise brimonidine. | 08-12-2010 |
20110003823 | Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage - The invention provides compositions and methods for treating diseases and conditions, including systemic diseases and conditions, through an intravenous administration of a selective α-2 adrenergic receptor agonists having a binding affinity of 300 fold or greater for α-2 over α-1 adrenergic receptors. The amounts of the selective α-2 adrenergic receptor agonists are substantially lower than the amounts normally used to cause sedation. The compositions preferably include dexmedetomidine. | 01-06-2011 |
20110044970 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DRY EYE - The invention generally relates to methods and compositions for treating dry eye and related conditions by administering compositions comprising compounds that increase capillary permeability of either the lacrimal gland, accessory lacrimal gland, or ocular surface. | 02-24-2011 |
20110152271 | Compositions and methods for ophthalmic delivery of nasal decongestants - The invention provides compositions and methods for treating nasal congestion through ophthalmic delivery. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine. | 06-23-2011 |
20110160214 | Compositions and methods for eye whitening - The invention provides compositions and methods for whitening of eyes. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine. | 06-30-2011 |
20110244058 | Compositions and methods for treatment of pulmonary diseases and conditions - The invention provides compositions and methods for treating pulmonary diseases and conditions. The provided compositions and methods utilize either low concentrations of selective α-2 adrenergic receptor agonists having a binding affinity of 300 fold or greater for α-2 over α-1 adrenergic receptors or ketamine at specific pH. The compositions preferably comprise brimonidine and/or dexmedetomidine and/or ketamine. | 10-06-2011 |
20110257188 | Compositions and methods for the treatment of nasal conditions - The invention provides compositions and methods for treating nasal congestion. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine. | 10-20-2011 |
20120156244 | Nasal Compositions and Uses Thereof - Pharmaceutical compositions for the treatment of nasal congestion, wherein the pharmaceutical compositions comprise low concentrations of a super-selective subclass of selective α-2 adrenergic receptor agonists. Methods of using the compositions for the treatment of nasal congestion, cerebrovascular disease or systemic conditions, and as delivery vehicles to deliver other active agents to treat systemic or cerebrovascular diseases or conditions. | 06-21-2012 |
20120202863 | Compositions and methods for treatment of glaucoma - The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine at near alkaline pH and extremely low concentrations. | 08-09-2012 |
20120202864 | Compositions and Methods for Treatment of Glaucoma - The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine at acidic pH and extremely low concentrations. | 08-09-2012 |
20120277239 | Compositions and Methods for Improving Night Vision - The invention provides compositions and methods for improving night vision without inducing redness or significant tachyphylaxis. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine. | 11-01-2012 |
20120309720 | COMPOSITIONS AND METHODS FOR TREATMENT OF GLAUCOMA - The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine. | 12-06-2012 |
20120309804 | COMPOSITIONS AND METHODS FOR TREATMENT OF GLAUCOMA - The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine. | 12-06-2012 |
20120328687 | FORMULATIONS OF SELECTIVE ALPHA-2 AGONISTS AND METHODS OF USE THEREOF - The invention provides compositions and methods utilizing low concentrations of selective α-2 adrenergic receptor agonists, preferably, brimonidine. The invention provides contact lens solutions and methods of using these solutions for pre-soaking contact lenses to achieve reduction of redness and/or increase in whitening of eyes. The invention also provides compositions including a selective α-2 adrenergic receptor agonist in a combination with an ocular medical device, including but not limited to a bandage lens. The invention also provides combination compositions including a selective α-2 adrenergic receptor agonist and another active agent for the treatment of an ocular condition, including but not limited to glaucoma and/or a condition associated with eye redness. | 12-27-2012 |
20130143938 | Compositions and Methods for the Treatment of Migraine - Pharmaceutical compositions for the treatment of nasal congestion or migraine, wherein the pharmaceutical compositions comprise low concentrations of a super-selective subclass of selective α-2 adrenergic receptor agonists. | 06-06-2013 |
20130172357 | Compositions and Methods for Treatment of Glaucoma - The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine. | 07-04-2013 |
20130345229 | Compositions and Methods for the Treatment of Nasal Conditions - The invention provides compositions and methods for treating nasal congestion. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine. | 12-26-2013 |
20140038973 | Compositions and Methods for Eye Whitening - The invention provides compositions and methods for whitening of eyes. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine. | 02-06-2014 |
20140038974 | Compositions and Methods for Eye Whitening - The invention provides compositions and methods for whitening of eyes and/or reducing redness of eyes. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine, dexmedetomidine, guanfacine or fadolmidine. | 02-06-2014 |
20140107173 | Compositions and Methods for Treatment of Glaucoma - The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine. | 04-17-2014 |
20140163080 | Compositions and Methods for Treatment of Glaucoma - The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine. | 06-12-2014 |
20140377210 | ARTIFICIAL TEAR COMPOSITIONS - The invention provides artificial tear compositions comprising one or more nonionic surfactants with one or more non-Newtonian viscosity enhancing excipients. | 12-25-2014 |
20140378361 | CONTACT LENS CLEANING COMPOSITIONS - The invention provides a contact lens cleaning composition comprising at least two nonionic surfactants and optionally including a non-Newtonian viscosity enhancing excipient. | 12-25-2014 |
20140378391 | Ophthalmic Lipophilic Drug Delivery Vehicle Formulations - The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly modified to provide an artificial tear formulation. | 12-25-2014 |
20140378401 | Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations - The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly modified to provide an artificial tear formulation. | 12-25-2014 |
20150031705 | OPHTHALMIC FORMULATIONS INCLUDING SELECTIVE ALPHA 1 ANTAGONISTS - Ophthalmic formulations are provided. The ophthalmic formulations include one or more active agents that act to optimize pupil light reflex while minimizing, or effectively eliminating, any undesired eye redness in response to application thereof. The active agents include, for example, alpha 1 antagonists, such as alpha 1a selective antagonists. | 01-29-2015 |
20150065511 | Compositions and Methods for the Treatment of Presbyopia - The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably use aceclidine separate or together with a cycloplegic agent and/or with a nonionic surfactant and viscosity enhancer, and or with low concentrations of a selective α-2 adrenergic receptor agonist. | 03-05-2015 |